These summary findings highlight the effect of Lp(a) on CAVD initiation, progression and outcomes, and support the early onset of Lp(a)-related subclinical lesions before clinical evidence. The gene discussed is LPA; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.